Evidence map›Paper›PMID 24348985›Full record

ArticlePloS one2013

Risk of severe upper gastrointestinal complications among oral bisphosphonate users.

Arianna Ghirardi, Lorenza Scotti, Antonella Zambon, Gianluca Della Vedova, Luca Cavalieri D'oro, Francesco Lapi, Francesco Cipriani, Achille P Caputi, Alberto Vaccheri, Dario Gregori and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Arianna GhirardiDepartment of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, University of Milano-Bicocca, Milan, Italy.
Lorenza ScottiDepartment of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, University of Milano-Bicocca, Milan, Italy.
Antonella ZambonDepartment of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, University of Milano-Bicocca, Milan, Italy.
Gianluca Della VedovaDepartment of Informatics, Systems and Communications, University of Milano-Bicocca, Milan, Italy.
Luca Cavalieri D'oroOperative Unit of Epidemiology, Local Health Unit of Monza, Monza-Brianza, Italy.
Francesco LapiDepartment of Epidemiology, Regional Agency for Healthcare Services of Tuscany, Florence, Italy ; Department of Preclinical and Clinical Pharmacology, University of Florence, Florence Italy ; Centre for Clinical Epidemiology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Francesco CiprianiDepartment of Epidemiology, Regional Agency for Healthcare Services of Tuscany, Florence, Italy.
Achille P CaputiDepartment of Medicine and Pharmacology, University of Messina, Messina, Italy.
Alberto VaccheriRegional Centre for Drug Evaluation and Information (CREVIF), Department of Pharmacology, University of Bologna, Bologna, Italy.
Dario GregoriDepartment of Public Health and Microbiology, University of Turin, Turin, Italy.
Rosaria GesuitaCenter of Epidemiology, Biostatistics, and Medical Information Technology, Polytechnic University of Marche, Ancona, Italy.
Annarita VestriDepartment of Experimental Medicine and Pathology, University "La Sapienza", Rome, Italy.
Tommaso StanisciaDepartment of Medicine and Aging, University "G. d'Annunzio", Chieti-Pescara, Italy.
Giampiero MazzagliaDepartment of Epidemiology, Regional Agency for Healthcare Services of Tuscany, Florence, Italy.
Giovanni CorraoDepartment of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, University of Milano-Bicocca, Milan, Italy.
BEST Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral bisphosphonates (BPs) are the primary agents for the treatment of osteoporosis. Although BPs are generally well tolerated, serious gastrointestinal adverse events have been observed.

aimTo assess the risk of severe upper gastrointestinal complications (UGIC) among BP users by means of a large study based on a network of Italian healthcare utilization databases.

methodsA nested case-control study was carried out by including 110,220 patients aged 45 years or older who, from 2003 until 2005, were treated with oral BPs. Cases were the 862 patients who experienced the outcome (hospitalization for UGIC) until 2007. Up to 20 controls were randomly selected for each case. Conditional logistic regression model was used to estimate odds ratio (OR) associated with current use of BPs after adjusting for several covariates. A set of sensitivity analyses was performed in order to account for sources of systematic uncertainty.

resultsThe adjusted OR for current use of BPs with respect to past use was 0.94 (95% CI 0.81 to 1.08). There was no evidence that this risk changed either with BP type and regimen, or concurrent use of other drugs or previous hospitalizations.

conclusionsNo evidence was found that current use of BPs increases the risk of severe upper gastrointestinal complications compared to past use.

Indexed as

Administration, OralAgedAged, 80 and overBone Density Conservation AgentsCase-Control StudiesDiphosphonatesFemaleGastrointestinal DiseasesHumansLogistic ModelsMaleMiddle AgedOdds RatioOsteoporosisBone Density Conservation AgentsDiphosphonates

Identifiers

PMID24348985
PMCPMC3857168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.